Please find attached herewith Annual Secretarial Compliance Report for the year ended on March 31, 2025
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences has filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2025, as required under Regulation 24A of SEBI's Listing Regulations. Practicing Company Secretary Prince Chadha reviewed the company's compliance and confirmed the firm has adhered to all applicable SEBI regulations, secretarial standards, and disclosure norms during FY25. No penalties, fines, or show-cause notices were issued by SEBI or stock exchanges against the company in the year. A few minor observations were noted (such as delayed disclosure of certain litigation in April 2024 and receipt of an SEBI summons regarding an old GST matter), but the company responded adequately and compliance was deemed made good.
This is a routine annual compliance filing with no material adverse findings, signaling good corporate governance for shareholders. The pending sub-judice matter at the Supreme Court (relating to a prior regulation 17(1A) issue where SAT ruled in the company's favor) remains a watch item but is not a new development.